Company / Cost of Revenue
Actinium Pharmaceuticals, Inc. Cost of Revenue History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$900.0K
FY2021
5-year range
$900.0K / $900.0K
FY2017-FY2021
Trend
-
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$900,000 in FY2021.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $900.0K | - |
| FY2011 | $0 | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026